论文信息 - Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations. - 字舞流文

Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations.

V. Lougaris | R. Badolato | S. Giliani | A. Biondi | G. Cazzaniga | A. Plebani | F. Penco | M. Gattorno | D. Moratto | L. Imberti | G. Gaipa | P. Corti | C. Bugarin | G. Fazio | M. Baronio | M. Chiarini | L. Gazzurelli | S. Paghera | F. Saettini | M. Quadri | Luisa Imberti | G. Gaipa | A. Biondi | A. Plebani | Giovanni Cazzaniga | M. Gattorno | Manuela Baronio | Paola Corti | Simone Paghera

[1] R. Geha,et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). , 2020, The Journal of allergy and clinical immunology.

[2] V. Lougaris,et al. A novel monoallelic gain of function mutation in p110δ causing atypical activated phosphoinositide 3-kinase δ syndrome (APDS-1). , 2019, Clinical immunology.

[3] I. Meyts,et al. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment , 2018, Journal of Clinical Immunology.

[4] S. Mustjoki,et al. ADA2 deficiency: Clonal lymphoproliferation in a subset of patients , 2018, The Journal of allergy and clinical immunology.

[5] G. Damonte,et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study , 2017, Annals of the rheumatic diseases.

[6] T. Loughran,et al. LGL leukemia: from pathogenesis to treatment. , 2017, Blood.

[7] P. Nederkoorn,et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. , 2016, Rheumatology.

[8] M. King,et al. Mutant ADA2 in vasculopathies. , 2014, The New England journal of medicine.

[9] J. Mullikin,et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. , 2014, The New England journal of medicine.

[10] C. Wouters,et al. Mutant ADA2 in vasculopathies. , 2014, The New England journal of medicine.

[11] M. Wlodarski,et al. Pathophysiology Defined by Altered Signal Transduction Pathways: The Role of JAK-STAT and PI3K Signaling in Leukemic Large Granular Lymphocytes , 2006, Cell cycle.

[12] M. Wlodarski,et al. Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. , 2005, Blood.